Petruff C A, Bedford A, Gordon F D, Chopra S
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass 02215, USA.
Dig Dis. 1997 Jan-Apr;15(1-2):1-22. doi: 10.1159/000171585.
Viral hepatitis accounts for substantial morbidity and mortality worldwide, To date, the molecular sequences of six hepatotropic viruses have been described and designated hepatitis A, B, C, D, E, and G. Various methods have been employed to decrease the occurrence of these diseases, and advances in vaccination strategies have aided in prevention of viral hepatitis. There are currently two FDA-approved vaccines licensed for use in the United States, aimed at eradication of hepatitis A and hepatitis B viral infection. A considerable amount of research has been devoted to the development of these vaccines, and progress has been made toward the development of vaccines aimed at the other hepatotropic viruses. In this article, the development and current status of the vaccines directed against the hepatitis viruses are reviewed.
病毒性肝炎在全球范围内导致了大量的发病和死亡。迄今为止，已描述了六种嗜肝病毒的分子序列，并将其命名为甲型、乙型、丙型、丁型、戊型和庚型肝炎病毒。人们采用了各种方法来减少这些疾病的发生，疫苗接种策略的进展有助于预防病毒性肝炎。目前有两种经美国食品药品监督管理局（FDA）批准许可在美国使用的疫苗，旨在根除甲型和乙型肝炎病毒感染。大量研究致力于这些疫苗的研发，针对其他嗜肝病毒的疫苗研发也取得了进展。本文对针对肝炎病毒的疫苗的研发及现状进行了综述。
